• 1
    Poewe W. Non-motor symptoms in Parkinson's disease. Eur J Neurol 2008; 15( Suppl 1): 1420.
  • 2
    Wolters EC,Tesselaar HJ. International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. J Neurol 1996; 243: 235240.
  • 3
    Högl B,Rothdach A,Wetter TC,Trenkwalder C. The effect of cabergoline on sleep, periodic leg movements in sleep, and early morning motor function in patients with Parkinson's disease. Neuropsychopharmacology 2003; 28: 18661870.
  • 4
    Romigi A,Stanzione P,Marciani MG, et al. Effect of cabergoline added to levodopa treatment on sleep-wake cycle in idiopathic Parkinson's disease: an open label 24-hour polysomnographic study. J Neural Transm 2006; 113: 19091913.
  • 5
    Rektorova I,Balaz M,Svatova J, et al. Effects of ropinirole on nonmotor symptoms of Parkinson disease: a prospective multicenter study. Clin Neuropharmacol 2008; 31: 261266.
  • 6
    Grandas F,Martínez-Martín P,Linazasoro G. Quality of life in patients with Parkinson's disease who transfer from standard levodopa to Sinemet CR: the STAR Study.The STAR Multicenter Study Group. J Neurol 1998; 245( Suppl 1): S31S33.
  • 7
    Rascol O,Perez-Lloret S. Rotigotine transdermal delivery for the treatment of Parkinson's disease. Expert Opin Pharmacother 2009; 10: 677691.
  • 8
    Pham DQ,Nogid A. Rotigotine transdermal system for the treatment of Parkinson's disease. Clin Ther 2008; 30: 813824.
  • 9
    Pahwa R,Poewe W,Lyons KE,Boroojerdi B. Changes in early morning motor status following adjunctive treatment of advanced Parkinson's disease with rotigotine transdermal system in two large, placebo-controlled trials (PREFER and CLEOPATRA-PD). Mov Disord 2009; 24: S280.
  • 10
    Martínez-Martín P,Gil-Nagel A,Gracia LM,Gómez JB,Martinez-Sarriés J,Bermejo F. Unified Parkinson's Disease Rating Scale characteristics and structure.The Cooperative Multicentric Group. Mov Disord 1994; 9: 7683.
  • 11
    Trenkwalder C,Kohnen R,Högl B, et al. Parkinson disease sleep scale—Validation of the Revised Version PDSS-2. Mov Disord 2010 (in press).
  • 12
    Stocchi F,Barbato L,Nordera G,Berardelli A,Ruggieri S. Sleep disorders in Parkinson's disease. J Neurol 1998; 245( Suppl 1): S158.
  • 13
    Martinez-Martin P,Rodriguez-Blazquez C,Abe K, et al. International study on the psychometric attributes of the Non-Motor Symptoms Scale in Parkinson disease. Neurology 2009; 73: 15841591.
  • 14
    Visser M,Leentjens AF,Marinus J,Stiggelbout AM,van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord 2006; 21: 668672.
  • 15
    Peto V,Jenkinson C,Fitzpatrick R. PDQ-39: a review of the development, validation and application of a Parkinson's disease quality of life questionnaire and its associated measures. J Neurol 1998; 245( Suppl 1): S104.
  • 16
    Christenson GA,Faber RJ,de Zwaan M, et al. Compulsive buying: descriptive characteristics and psychiatric comorbidity. J Clin Psychiatry 1994; 55: 511
  • 17
    Honig H,Antonini A,Martinez-Martin P, et al. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Mov Disord 2009; 24: 14681474.
  • 18
    Pahwa R,Stacy MA,Factor SA, et al. Ropinirole 24-hour prolonged release: randomized, controlled study in advanced Parkinson disease. Neurology 2007; 68: 11081115.
  • 19
    Parkinson Study Group. A controlled trial of rotigotine monotherapy in early Parkinson's disease. Arch Neurol 2003; 60: 17211728.
  • 20
    Giladi N,Mair KJ,Badenhorst F, et al. Effects of rotigotine transdermal patch on early morning motor function, sleep quality, and daytime sleepiness in patients with idiopathic Parkinson's disease. Results of a multicenter, multinational trial. Eur J Neurol. 2006; 13( Suppl. 2): 74[P1127].
  • 21
    Chaudhuri KR,Pal S,DiMarco A, et al. The Parkinson's disease sleep scale: a new instrument for assessing sleep and nocturnal disability in Parkinson's disease. J Neurol Neurosurg Psychiatry 2002; 73: 629635.
  • 22
    Martínez-Martín P,Salvador C,Menéndez-Guisasola L, et al. Parkinson's disease sleep scale: validation study of a Spanish version. Mov Disord 2004; 19: 12261232.
  • 23
    Margis R,Donis K,Schönwald SV, et al. Psychometric properties of the Parkinson's disease sleep scale—Brazilian version. Parkinsonism Relat Disord 2009; 15: 495499.
  • 24
    Uemura Y,Nomura T,Inoue Y, et al. Validation of the Parkinson's disease sleep scale in Japanese patients: a comparison study using the Pittsburgh Sleep Quality Index, the Epworth Sleepiness Scale and Polysomnography. J Neurol Sci 2009; 287: 3640.
  • 25
    Wang G,Cheng Q,Zeng J, et al. Sleep disorders in Chinese patients with Parkinson's disease: validation study of a Chinese version of Parkinson's disease sleep scale. J Neurol Sci 2008; 271: 153157.
  • 26
    Eggert K,Schrader C,Hahn M, et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clin Neuropharmacol 2008; 31: 151166.
  • 27
    Katzenschlager R,Hughes A,Evans A, et al. Continuous subcutaneous apomorphine therapy improves dyskinesias in Parkinson's disease: a prospective study using single-dose challenges. Mov Disord 2005; 20: 151157.
  • 28
    Zesiewicz TA,Sullivan KL,Arnulf I, et al. Practice parameter: Treatment of nonmotor symptoms of Parkinson disease. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2010; 74: 924931.
  • 29
    Chaudhuri KR,Schapira AH. Non-motor symptoms of Parkinson's disease: dopaminergic pathophysiology and treatment. Lancet Neurol 2009; 8: 464474.
  • 30
    Etminan M,Gill S,Samii A. Comparison of the risk of adverse events with pramipexole and ropinirole in patients with Parkinson's disease: a meta-analysis. Drug Saf 2003; 26: 439444.